GSK Joins PRECISE–SG100K PCC as 5th Pharma Partner
GSK’s participation in the PRECISE–SG100K Pharma Pre Competitive Consortium (PCC) reflects growing industry recognition of Singapore’s National Precision Medicine (NPM) and the PRECISE- SG100K…
Read the full articleYou might also wanna read
Pan-European PRECISE consortium aims to predict cancer vulnerabilities before experimental testing
Dr Sumana Sharma is one of the founding partners of a major new pan-European initiative that aims to transform how scientists identify and t
imm.ox.ac.uk·1d ago
GSK agrees $10 billion deal for Nuvalent cancer drugs
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
GSK acquires cancer drug developer Nuvalent in $10.6 billion deal
Biotech firm is developing small molecules for lung cancers
cen.acs.org·1mo agoGSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’
Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to make them priority programs.
GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Deal would rank as one of UK drugmaker’s biggest as biotech M&A activity accelerates this year
ft.trib.al·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.